Details

Autor(en) / Beteiligte

• Vaidya, Jayant S
• Bulsara, Max
• Baum, Michael
• Wenz, Frederik
• Massarut, Samuele
• Pigorsch, Steffi
• Alvarado, Michael
• Douek, Michael
• Saunders, Christobel
• Flyger, Henrik
• Eiermann, Wolfgang
• Brew-Graves, Chris
• Williams, Norman R
• Potyka, Ingrid
• Roberts, Nicholas
• Bernstein, Marcelle
• Brown, Douglas
• Sperk, Elena
• Laws, Siobhan
• Sütterlin, Marc
• Corica, Tammy
• Lundgren, Steinar
• Holmes, Dennis
• Vinante, Lorenzo
• Bozza, Fernando
• Pazos, Montserrat
• Blanc-Onfroy, Magali Le
• Gruber, Günther
• Polkowski, Wojciech
• Dedes, Konstantin J
• Niewald, Marcus
• Blohmer, Jens
• McReady, David
• Hoefer, Richard
• Kelemen, Pond
• Petralia, Gloria
• Falzon, Mary
• Joseph, David
• Tobias, Jeffrey S

Titel

New clinical and biological insights from the international TARGIT-A randomised trial of targeted intraoperative radiotherapy during lumpectomy for breast cancer

Ist Teil von

• British journal of cancer, 2021-08, Vol.125 (3), p.380-389

Ort / Verlag

England: Nature Publishing Group

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• The TARGIT-A trial reported risk-adapted targeted intraoperative radiotherapy (TARGIT-IORT) during lumpectomy for breast cancer to be as effective as whole-breast external beam radiotherapy (EBRT). Here, we present further detailed analyses. In total, 2298 women (≥45 years, invasive ductal carcinoma ≤3.5 cm, cN0-N1) were randomised. We investigated the impact of tumour size, grade, ER, PgR, HER2 and lymph node status on local recurrence-free survival, and of local recurrence on distant relapse and mortality. We analysed the predictive factors for recommending supplemental EBRT after TARGIT-IORT as part of the risk-adapted approach, using regression modelling. Non-breast cancer mortality was compared between TARGIT-IORT plus EBRT vs. EBRT. Local recurrence-free survival was no different between TARGIT-IORT and EBRT, in every tumour subgroup. Unlike in the EBRT arm, local recurrence in the TARGIT-IORT arm was not a predictor of a higher risk of distant relapse or death. Our new predictive tool for recommending supplemental EBRT after TARGIT-IORT is at https://targit.org.uk/addrt . Non-breast cancer mortality was significantly lower in the TARGIT-IORT arm, even when patients received supplemental EBRT, HR 0.38 (95% CI 0.17-0.88) P = 0.0091. TARGIT-IORT is as effective as EBRT in all subgroups. Local recurrence after TARGIT-IORT, unlike after EBRT, has a good prognosis. TARGIT-IORT might have a beneficial abscopal effect. ISRCTN34086741 (21/7/2004), NCT00983684 (24/9/2009).